BridgeBio Pharma’s $150 Million Common Stock Public Offering

Goodwin Procter advised BridgeBio Pharma on the offering, and Latham & Watkins advised the underwriters involved.BridgeBio Pharma, Inc. announced the pricing on March 7, 2023 of an…

This content is for members only.
Login to Read More Join Now

PrintFriendly

Synthego Corporation v. Agilent Technologies, Inc.

US Foods Holding Corp’s Secondary Public Offering of Common Stock

ElevateBio’s $401 Million Series D Financing Round

Molinos Agro’s US$250 Million Financing

Industrial and Commercial Bank of China (Argentina)’s US$250 Million Debentures Program

Seacrest Petróleo’s US$300 Million Financing for the Acquisition of Polo Norte Capixaba

Emilshus’ Acquisition of a Property

Beem Energy’s EUR20 Million Funding Round

HB Aesthetics’ LBO

Telecom Egypt SAE’s Sale of Shares on the Secondary Market at EGX

Scatec’s Joint Development Agreement with Alexandria National Refining and Petrochemicals Company

FMO and CAP’s Co-Investment in Merensky Timber

Volumez’s $20 Million Series A Financing

Helios’ Acquisition of Interest in Tlamim Project

Gav Yam’s Bonds Offering

OFX’s Acquisition of Paytron

Australian Silicon Valley’s Investment in Fetch Metals Limited

Gera Developments’ NCD Offering

Paul Hastings Adds Litigation Partner Susan Leader in Century City

Weil Adds Energy Partner Chris Bennett in Houston

Linklaters Continues U.S. Expansion with Arrival of Market-Leading Litigation Partner Robin Nunn

Presumption of “Tax Inversion”: The Italian Supreme Court Clarifues That “Mediated” Control Is Not Relevant

Italian DPA: Company Fined For Failure To Monitor Its Suppliers

The (Un)Happy Relationship Between SIAE And Meta in Italy

Paul Hastings Adds Litigation Partner Susan Leader in Century City

Weil Adds Energy Partner Chris Bennett in Houston

Linklaters Continues U.S. Expansion with Arrival of Market-Leading Litigation Partner Robin Nunn

BridgeBio Pharma’s $150 Million Common Stock Public Offering

Author: Pietro Martinoia